As demonstrated by the LNCap and RWPE studies [47], [56], genistein-activated ERβ may stimulate the EGFR/Src signaling pathway, which leads to increased proliferation, reduced apoptosis and tumor progression in our model. The gene discussed is ESR2; the disease is neoplasm.